| Patent application number | Description | Published |
|---|
| 20080302272 | NONPOLAR AND SOLID OR PHASE CHANGE INK COMPOSITIONS COMPRISING QUINACRIDONE NANOSCALE PIGMENT PARTICLES - A nonpolar or solid or phase change ink composition which includes a carrier and a nanoscale pigment particle composition, which nanoscale pigment particle composition includes a quinacridone pigment molecules including at least one functional moiety, and a sterically bulky stabilizer compound including at least one functional group, the functional moiety of the pigment associates non-covalently with the functional group of the stabilizer, and the presence of the associated stabilizer limits the extent of particle growth and aggregation, to afford nanoscale-sized particles. | 12-11-2008 |
| 20100083869 | FLUORESCENT NANOSCALE PARTICLES - A nanoscale pigment particle composition includes a fluorescent compound, such as a benzothioxanthene pigment, including at least one functional moiety, and a stabilizer compound including at least one functional group, wherein the functional moiety associates non-covalently with the functional group; and the presence of the associated stabilizer limits the extent of particle growth and aggregation, to afford nanoscale-sized particles. | 04-08-2010 |
| 20100086683 | FLUORESCENT SOLID INK MADE WITH FLUORESCENT NANOPARTICLES - A nonpolar or solid (or phase change) ink composition that includes a carrier and at least one nanoscale fluorescent pigment particle composition and/or a fluorescent organic nanoparticle composition. The fluorescent organic nanoparticle composition includes a polymeric matrix obtained by modified EA latex process and/or emulsion polymerization and one or more fluorescent dyes and the nanoscale fluorescent pigment particle composition includes pigment molecules with at least one functional moiety, and a sterically bulky stabilizer compound including at least one functional group, the functional moiety of the pigment associates non-covalently with the functional group of the stabilizer. | 04-08-2010 |
| 20100086701 | RADIATION CURABLE INK CONTAINING FLUORESCENT NANOPARTICLES - Radiation curable compositions, such as UV curable ink compositions, contain a polymeric dispersant, a curable material, that includes a carrier and at least one nanoscale fluorescent pigment particle and an optional non-fluorescent colorant. The fluorescent organic nanoparticle composition includes one or more fluorescent dyes dispersed in a polymeric matrix obtained by modified EA latex process or by emulsion polymerization. In a different embodiment, the nanoscale fluorescent pigment particle composition includes pigment molecules with at least one functional moiety, and a sterically bulky stabilizer compound including at least one functional group, the functional moiety of the pigment associates non-covalently with the functional group of the stabilizer, and the presence of the associated stabilizer limits the extent of particle growth and aggregation, to afford nanoscale-sized pigment particles. | 04-08-2010 |
| 20100086867 | TONER CONTAINING FLUORESCENT NANOPARTICLES - A method for making toners to include at least one nanoscale fluorescent pigment particle composition and/or a fluorescent organic nanoparticle composition. The particles are incorporated into emulsion of toner and used in making toner via emulsion aggregation. Such toners may have a core and/or a shell and the clay composites may be included within the core, the shell or both. The fluorescent organic nanoparticle composition includes a polymeric matrix obtained by modified EA latex process and/or emulsion polymerization and one or more fluorescent dyes and the nanoscale fluorescent pigment particle composition includes pigment molecules with at least one functional moiety, and a sterically bulky stabilizer compound including at least one functional group, the functional moiety of the pigment associates non-covalently with the functional group of the stabilizer, and the presence of the associated stabilizer limits the extent of particle growth and aggregation, to afford nanoscale-sized pigment particles. | 04-08-2010 |
| 20110265687 | FLUORESCENT INK COMPOSITIONS AND FLUORESCENT PARTICLES - A fluorescent solid ink, and a method for making such ink, including an ink vehicle and a fluorescent particle. The fluorescent particle includes a fluorescent pigment, such as a trans-dicarboxylic-indenofluorenone, and at least one stabilizing wax chemically attached to the fluorescent pigment. The stabilizing wax includes an amine group at its terminal end and the fluorescent pigment includes at least one carboxylic acid group, where the amine group reacts with the carboxylic acid group to form an amide bond. | 11-03-2011 |
| 20110269065 | FLUORESCENT TONER COMPOSITIONS AND FLUORESCENT PIGMENTS - A fluorescent particle includes a fluorescent pigment, such as a trans-dicarboxylic-indenofluorenone, and at least one stabilizing wax chemically attached to the fluorescent pigment. The stabilizing wax includes an amine group at its terminal end and the fluorescent pigment includes at least one carboxylic acid group, where the amine group reacts with the carboxylic acid group to form an amide bond. A method for making fluorescent particles for use in toners by chemically attaching at least one stabilizing wax to a fluorescent pigment where the at least one stabilizing wax includes an amine group at its terminal end and the fluorescent pigment includes at least one carboxylic acid group. A toner may include a resin and the fluorescent particle. | 11-03-2011 |
| Patent application number | Description | Published |
|---|
| 20090149635 | ANTIBODIES TO HUMAN ZCYTOR17 LIGAND - The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody molecules. The zcytor17lig is a novel cytokine. The polypeptides may be used within methods for stimulating the immune system, and proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto. | 06-11-2009 |
| 20090192292 | MURINE ZCYTOR17 LIGAND POLYPEPTIDES AND POLYNUCLEOTIDES - The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody molecules. The zcytor17lig is a novel cytokine. The polypeptides may be used within methods for stimulating the immune system, and proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto. | 07-30-2009 |
| 20090274694 | CYTOKINE RECEPTOR ZCYTOR17 MULTIMERS - Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto. | 11-05-2009 |
| 20100055101 | CYTOKINE RECEPTOR ZCYTOR17 MULTIMERS - Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto. | 03-04-2010 |
| 20100266499 | CYTOKINE RECEPTOR ZCYTOR17 MULTIMERS - Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto. | 10-21-2010 |
| 20100266597 | CYTOKINE RECEPTOR ZCYTOR17 MULTIMERS - Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto. | 10-21-2010 |
| 20110196128 | MURINE ZCYTOR17 LIGAND POLYNUCLEOTIDES - The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody molecules. The zcytor17lig is a novel cytokine. The polypeptides may be used within methods for stimulating the immune system, and proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto. | 08-11-2011 |
| 20110318354 | CYTOKINE RECEPTOR ZCYTOR17 MULTIMERS - Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto. | 12-29-2011 |
